

Press release

NeuroVive Pharmaceutical AB (publ)
556595-6538



Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 31 May 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharmaceutical AB, approved at the Extraordinary General Meeting on 22 March 2018.

Today, the last trading day of the month, there are in total 91,570,841 shares and votes in NeuroVive Pharmaceutical AB.

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CEST on 31 May 2018.

For more information please contact:

Daniel Schale, Director of Communications, NeuroVive
+46 (0)46-275 62 21, ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@neurovive.com, www.neurovive.com

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®) and one project in clinical phase I (KL1333) for genetic mitochondrial diseases. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH. The company's strategy is to advance drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).